Identification of guanine nucleotide-binding protein γ-7 as an epigenetically silenced gene in head and neck cancer by gene expression profiling

International Journal of Oncology

Volumn 42, Issue 4, 2013, Pages 1427-1436

  Demokan, Semra ^a,d   Chuang, Alice Y ^a   Chang, Xiaofei ^a   Khan, Tanbir ^a   Smith, Ian M ^a   Pattani, Kavita M ^a   Dasgupta, Santanu ^a,e   Begum, Shahnaz ^b   Khan, Zubair ^a   Liegeois, Nanette J ^a   Westra, William H ^b   Sidransky, David ^a   Koch, Wayne ^a   Califano, Joseph A ^a,c  

^a Department of Otolaryngology Head and Neck Surgery ^*  (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c GREATER BALTIMORE MEDICAL CENTER   (United States)

^d ISTANBUL UNIVERSITY   (Turkey)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Epigenetics; Gene expression; Guanine nucleotide binding protein 7; Head and neck squamous cell carcinoma; Silencing

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA 7; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; MALE; METHYLATION; MICROARRAY ANALYSIS; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; GTP-BINDING PROTEIN GAMMA SUBUNITS; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84874642736     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1808     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006.
2. Fearon ER and Vogelstein B: A genetic model of colorectal tumorigenesis. Cell 61:759-767, 1990.
3. Baylin SB, Herman JG, Graff JR, Vertino PM and Issa JP: Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72:141-196, 1998.
4. Dulaimi E, Hillinck J, Ibanez De Caceres I, Al-Saleem T and Cairns P: Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 10:6189-6193, 2004.
5. Leonhardt H and Cardoso MC: DNA methylation, nuclear structure, gene expression and cancer. J Cell Biochem 35(Suppl):S78-S83, 2000.
6. Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-2054, 2003.
7. Yamashita K, Upadhyay S, Osada M, et al: Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2:485-495, 2002.
8. Bernard PS and Wittwer CT: Real-time PCR technology for cancer diagnostics. Clin Chem 48:1178-1185, 2002.
9. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C and Shibata D: MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28:E32, 2000.
10. Cottrell SE and Laird PW: Sensitive detection of DNA methylation. Ann NY Acad Sci 983:120-130, 2003.
11. 1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 93:1747-1752, 2001.
12. Tokumaru Y, Yamashita K, Osada M, et al: Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res 64:5982-5987, 2004.
13. Li C and Wong WH: Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection. Proc Natl Acad Sci USA 98:31-36, 2001.
14. Tusher VG, Tibshirani R and Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116-5121, 2001.
15. Carvalho AL, Jeronimo C, Kim MM, et al: Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res 14:97-107, 2008.
16. Li LC and Dahiya R: MethPrimer: designing primers for methylation PCRs. Bioinformatics 18:1427-1431, 2002.
17. Giefing M, Arnemann J, Martin-Subero JI, et al: Identification of candidate tumour suppressor gene loci for Hodgkin and Reed-Sternberg cells by characterisation of homozygous deletions in classical Hodgkin lymphoma cell lines. Br J Haematol 142:916-924, 2008.
18. Ray K, Kunsch C, Bonner LM and Robishaw JD: Isolation of cDNA clones encoding eight different human G protein gamma subunits, including three novel forms designated the gamma-4, gamma-10, and gamma-11 subunits. J Biol Chem 270:21765-21771, 1995.
19. Shibata K, Mori M, Tanaka S, Kitano S and Akiyoshi T: Identification and cloning of human G-protein gamma 7, downregulated in pancreatic cancer. Biochem Biophys Res Commun 246:205-209, 1998.
20. Ohta M, Mimori K, Fukuyoshi Y, et al: Clinical significance of the reduced expression of G protein gamma 7 (GNG7) in oesophageal cancer. Br J Cancer 98:410-417, 2008.
21. Wang M, Gong B, Li Y and Wang Y: Human G-protein gamma 7 in extrahepatic cholangiocarcinoma and its clinicopathological significance. Hematol Oncol Stem Cell Ther 3:66-70, 2010.
22. Wollman EE, D'Auriol L, Rimsky L, et al: Cloning and expression of a cDNA for human thioredoxin. J Biol Chem 263:15506-15512, 1988.
23. Meng L, Wong JH, Feldman LJ, Lemaux PG and Buchanan BB: A membrane-associated thioredoxin required for plant growth moves from cell to cell, suggestive of a role in intercellular communication. Proc Natl Acad Sci USA 107:3900-3905, 2010.
24. Nishiyama A, Matsui M, Iwata S, et al: Identification of thioredoxin-binding protein-2/vitamin D (3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 274:21645-21650, 1999.
25. 3 inhibits tumor cell growth by blocking cell-cycle progression. Oncogene 22:4035-4046, 2003.
26. Fischer WH and Schubert D: Characterization of a novel plateletderived growth factor-associated protein. J Neurochem 66:2213-2216, 1996.
27. Kondo M, Ji L, Kamibayashi C, et al: Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells. Oncogene 20:6258-6262, 2001.
28. Ivanova AV, Ivanov SV, Prudkin L, et al: Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. Mol Cancer 8:91, 2009.
29. Zhou YB, Huang ZX, Ren CP, Zhu B and Yao KT: Screening and preliminary analysis of the apoptosis-and proliferation-related genes in nasopharyngeal carcinoma. Nan Fang Yi Ke Da Xue Xue Bao 29:645-647, 2009. (In Chinese).
30. Lerman MI and Minna JD: The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The international lung cancer chromosome 3p21.3 tumor suppressor gene consortium. Cancer Res 60:6116-6133, 2000.
31. Uno F, Sasaki J, Nishizaki M, et al: Myristoylation of the fus1 protein is required for tumor suppression in human lung cancer cells. Cancer Res 64:2969-2976, 2004.
32. Prudkin L, Behrens C, Liu DD, et al: Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Clin Cancer Res 14:41-47, 2008.
33. Hennessey PT, Ochs MF, Mydlarz WW, Hsueh W, Cope L, Yu W and Califano JA: Promoter methylation in head and neck squamous cell carcinoma cell lines is significantly different than methylation in primary tumors and xenografts. PLoS One 6:e20584, 2011.